Stockreport

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SAB Biotherapeutics, Inc.  (SABS) 
PDF SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy p [Read more]